Statins for primary prevention
Also known as: primary prevention statin · statin therapy
Free to read — no account needed. Sign in only to bookmark this disease and track your study progress.
Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication
U.S. Preventive Services Task Force (USPSTF) · 2022 · Final recommendation statement, 23 August 2022
The USPSTF's current statement on statins for adults who have not had a cardiovascular event. It ties the strength of the recommendation to estimated 10-year cardiovascular risk together with the presence of risk factors, and finds evidence insufficient at older ages.
- Grade B for adults aged 40 to 75 with at least one risk factor and an estimated 10-year cardiovascular risk of 10% or greater. source
- Grade C (selective offering) at estimated 10-year risk of 7.5% to under 10%, and Grade I (insufficient evidence) for adults aged 76 and older. source
- Does not apply to people with very high LDL cholesterol or familial hypercholesterolaemia, who are covered by other guidance; supersedes the 2016 statement. source
2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias
European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) · 2025 · 2025 focused update (European Heart Journal)
The European reference for lipid-lowering therapy, including statin use in people without established cardiovascular disease. This 2025 focused update revises selected recommendations of the 2019 ESC/EAS dyslipidaemia guidelines in light of evidence published up to 31 March 2025; the 2019 document otherwise remains in force.
- Published 29 August 2025 in the European Heart Journal as a focused update to, not a replacement of, the 2019 ESC/EAS dyslipidaemia guidelines. source
- Topics revised include high-dose statin plus ezetimibe combination therapy, intensification of lipid-lowering therapy during acute coronary syndrome admission, and lipoprotein(a) as a risk modifier. source
- Only evidence that would create new or changed Class I/IIa or Class III recommendations was included. source
US vs EU key differences
- Risk-estimation tools differ: the USPSTF anchors statin decisions on the ACC/AHA Pooled Cohort Equations, whereas the 2025 ESC/EAS focused update uses SCORE2 for adults up to about 69 and SCORE2-OP for ages 70-89. source
- The US recommendation is threshold-based: a B grade to prescribe a statin at ages 40-75 with at least one risk factor (dyslipidaemia, diabetes, hypertension or smoking) and 10-year CVD risk of 10% or more, and only a C grade for selective use in the 7.5% to under 10% band. source
- Older adults are handled differently: the USPSTF issues an I statement (insufficient evidence) for starting a statin at age 76 or older, while the European approach extends formal risk estimation up to age 89 through SCORE2-OP. source
- Treatment framing diverges: the USPSTF stops at whether to start a statin and sets no lipid target, whereas the ESC/EAS update keeps risk-based LDL-C goals and pushes faster intensification with combination therapy such as ezetimibe, bempedoic acid and inclisiran. source
- Version currency differs: the US statement dates from 2022, while the European guidance was refreshed by a 2025 focused update that also added Lp(a) and coronary artery calcium as risk-stratification modifiers. source
What changed recently
- EU2019 → 2025 focused update2025-01-01
The 2025 focused update leaves the 2019 LDL-cholesterol targets intact but changes how they are reached, pushing earlier and more aggressive combination therapy (high-intensity statin plus ezetimibe, including during the index acute coronary syndrome admission) and adding recommendations covering bempedoic acid, inclisiran and evinacumab. Risk stratification is refined with SCORE2/SCORE2-OP, lipoprotein(a) and coronary artery calcium scoring.
source ↗curation confidence 90% - US2016 → 20222022-08-23
The 2022 statement explicitly replaces the 2016 USPSTF statin recommendation and, after re-reviewing the trial evidence, retained the same structure: a B grade for adults aged 40-75 with at least one risk factor and 10-year cardiovascular risk of 10% or more, a C grade at 7.5% to under 10%, and an I statement for adults 76 and older.
See the full update feed for changes across every system.